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Background
Immunotherapy is transforming how cancer is treated,
and the Providence Portland Cancer Center has played
an important role in this progress through clinical trials
and pre-clinical research. However, even the most effica-
cious of these therapies only benefit a subset of patients
and frequently cause significant immune-related adverse
events (irAEs). Prognostic biomarkers that identify posi-
tively-responding patients, early in the course of therapy,
are essential for guiding treatment decisions and
improving patient outcomes. Evaluating how patients
are responding to an immunotherapy regimen, and
developing better treatment regimens, requires a
detailed analysis of each patient’s immune response to a
given therapy.
Despite tremendous progress, robust prognostic bio-
markers for clinical outcomes of cancer immunotherapy
and overall survival (OS) remain elusive. The prognostic
value of many putative biomarkers appears to erode as
the patient population becomes more diverse (e.g. differ-
ent cancer types, treatment regimens, etc). Furthermore,
the individual data sets that are generated by the multi-
ple analyses included in immunotherapy clinical trials
can be enormous. The combination of size and com-
plexity, along with the challenge of data normalization,
limits the utility of the data. Identifying reliable immu-
nological biomarkers for outcomes requires the ability
to compare numerous parameters, across a diverse
population of patients. Meeting this challenge requires
specialized software tools to normalize, integrate and
analyze these expansive data sets.
Methods and results
Our research team has developed a software platform
and series of algorithms that provide an innovative and
powerful solution to this challenge. The software auto-
mates the process of normalizing and integrating data
streams from disparate sources. The software can utilize
data from conventional clinical lab assays (e.g. CBC,
blood chem.), flow cytometry, transcriptomic, genomic,
proteomic, array-based (chemokine/cytokine, antibody)
and other data sets. Additionally, we have developed a
visualization platform that allows our clinicians and
scientists to access and interact with the data in a user-
friendly setting. Most importantly, we have developed a
novel algorithm to mine these integrated data sets for
biomarkers that are correlated with clinical outcomes.
Conclusions
This analytical platform has identified several putative bio-
markers with prognostic utility for checkpoint blockade
outcomes, and we are currently working to incorporate
the data sets from additional trials being conducted at our
institute.
Publicly accessible demonstrations of selected data
visualizations from this project can be accessed at
myCancerProject.org [http://www.mycancerproject.org].
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